Hengrui Medicine (600276.SH): HRS-1596 Tablets Receives Drug Clinical Trial Approval Notice

Zhitong Finance APP News, Hengrui Pharmaceuticals (600276.SH) announced that recently, its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for HRS-1596 tablets, approving the conduct of clinical trials of this product for weight management indications and type 2 diabetes indications.